Importer of Controlled Substances Application: Cerilliant Corporation, 43404-43407 [2017-19067]

Download as PDF 43404 Federal Register / Vol. 82, No. 178 / Friday, September 15, 2017 / Notices INTERNATIONAL TRADE COMMISSION [Investigation No. 337–TA–1071] Certain Wireless Audio Systems and Components Thereof Institution of Investigation U.S. International Trade Commission ACTION: Notice. AGENCY: Notice is hereby given that a complaint was filed with the U.S. International Trade Commission on August 10, 2017, under section 337 of the Tariff Act of 1930, as amended, on behalf of Broadcom Limited of San Jose, California and Avago Technologies General IP (Singapore) Pte. Ltd. of Singapore. An amended complaint was filed on August 16, 2017, and supplements to the amended complaint were filed on August 30, 2017. The amended complaint, as supplemented, alleges violations of section 337 based upon the importation into the United States, the sale for importation, and the sale within the United States after importation of certain wireless audio systems and components thereof by reason of infringement of U.S. Patent No. 6,684,060 (‘‘the ’060 patent’’). The amended complaint further alleges that an industry in the United States exists as required by the applicable Federal Statute. The complainants request that the Commission institute an investigation and, after the investigation, issue a limited exclusion order and cease and desist orders. ADDRESSES: The amended complaint, as supplemented, except for any confidential information contained therein, is available for inspection during official business hours (8:45 a.m. to 5:15 p.m.) in the Office of the Secretary, U.S. International Trade Commission, 500 E Street SW., Room 112, Washington, DC 20436, telephone (202) 205–2000. Hearing impaired individuals are advised that information on this matter can be obtained by contacting the Commission’s TDD terminal on (202) 205–1810. Persons with mobility impairments who will need special assistance in gaining access to the Commission should contact the Office of the Secretary at (202) 205– 2000. General information concerning the Commission may also be obtained by accessing its internet server at https://www.usitc.gov. The public record for this investigation may be viewed on the Commission’s electronic docket (EDIS) at https://edis.usitc.gov. FOR FURTHER INFORMATION CONTACT: Pathenia M. Proctor, The Office of mstockstill on DSK30JT082PROD with NOTICES SUMMARY: VerDate Sep<11>2014 18:16 Sep 14, 2017 Jkt 241001 Unfair Import Investigations, U.S. International Trade Commission, telephone (202) 205–2560. SUPPLEMENTARY INFORMATION: Authority: The authority for institution of this investigation is contained in section 337 of the Tariff Act of 1930, as amended, 19 U.S.C. 1337 and in section 210.10 of the Commission’s Rules of Practice and Procedure, 19 CFR 210.10 (2017). Scope of Investigation: Having considered the amended complaint, the U.S. International Trade Commission, on September 8, 2017, ordered that— (1) Pursuant to subsection (b) of section 337 of the Tariff Act of 1930, as amended, an investigation be instituted to determine whether there is a violation of subsection (a)(1)(B) of section 337 in the importation into the United States, the sale for importation, or the sale within the United States after importation of certain wireless audio systems and components thereof by reason of infringement of claim 20 of the ’060 patent; and whether an industry in the United States exists as required by subsection (a)(2) of section 337; (2) For the purpose of the investigation so instituted, the following are hereby named as parties upon which this notice of investigation shall be served: (a) The complainants are: Broadcom Limited, 1320 Ridder Park Drive, San Jose, CA 95131 Avago Technologies General IP (Singapore) Pte. Ltd., 1 Yinshun Avenue 7, Singapore, 768923 (b) The respondents are the following entities alleged to be in violation of section 337, and are the parties upon which the amended complaint is to be served: DTS, Inc., 5220 Las Virgenes Road, Calabasas, CA 91302 Phorus, Inc., 5220 Las Virgenes Road, Calabasas, CA 91302 MartinLogan, Ltd., 2101 Delaware Street, Lawrence, KS 66046–3149 Paradigm Electronics Inc., 205 Annagem Boulevard, Mississauga, ON L5T 2V1, Canada Anthem Electronics, Inc., 205 Annagem Boulevard, Mississauga, ON L5T 2V1, Canada Wren Sound Systems, LLC, 169 Gateshead Way, Phoenixville, PA 19460 McIntosh Laboratory, Inc., 2 Chambers Street, Binghamton, NY 13903–2699 Definitive Technology, 11433 Cronridge Drive, Suite K, Owings Mills, MD 21117 Polk Audio Inc., 1 Viper Way, Vista, CA 92081 (c) The Office of Unfair Import Investigations, U.S. International Trade PO 00000 Frm 00080 Fmt 4703 Sfmt 4703 Commission, 500 E Street SW., Suite 401, Washington, DC 20436; and (3) For the investigation so instituted, the Chief Administrative Law Judge, U.S. International Trade Commission, shall designate the presiding Administrative Law Judge. Responses to the amended complaint and the notice of investigation must be submitted by the named respondents in accordance with section 210.13 of the Commission’s Rules of Practice and Procedure, 19 CFR 210.13. Pursuant to 19 CFR 201.16(e) and 210.13(a), such responses will be considered by the Commission if received not later than 20 days after the date of service by the Commission of the amended complaint and the notice of investigation. Extensions of time for submitting responses to the amended complaint and the notice of investigation will not be granted unless good cause therefor is shown. Failure of a respondent to file a timely response to each allegation in the amended complaint and in this notice may be deemed to constitute a waiver of the right to appear and contest the allegations of the amended complaint and this notice, and to authorize the administrative law judge and the Commission, without further notice to the respondent, to find the facts to be as alleged in the amended complaint and this notice and to enter an initial determination and a final determination containing such findings, and may result in the issuance of an exclusion order or a cease and desist order or both directed against the respondent. By order of the Commission. Issued: September 11, 2017. Lisa R. Barton, Secretary to the Commission. [FR Doc. 2017–19597 Filed 9–14–17; 8:45 am] BILLING CODE 7020–02–P DEPARTMENT OF JUSTICE Drug Enforcement Administration [Docket No. DEA–392] Importer of Controlled Substances Application: Cerilliant Corporation ACTION: Notice of application. Registered bulk manufacturers of the affected basic classes, and applicants therefore, may file written comments on or objections to the issuance of the proposed registration on or before October 16, 2017. Such persons may also file a written request DATES: E:\FR\FM\15SEN1.SGM 15SEN1 43405 Federal Register / Vol. 82, No. 178 / Friday, September 15, 2017 / Notices for a hearing on the application on or before October 16, 2017. ADDRESSES: Written comments should be sent to: Drug Enforcement Administration, Attention: DEA Federal Register Representative/DRW, 8701 Morrissette Drive, Springfield, Virginia 22152. All requests for hearing must be sent to: Drug Enforcement Administration, Attn: Administrator, 8701 Morrissette Drive, Springfield, Virginia 22152. All requests for hearing should also be sent to: (1) Drug Enforcement Administration, Attn: Hearing Clerk/LJ, 8701 Morrissette Drive, Springfield, Virginia 22152; and (2) Drug Enforcement Administration, Attn: DEA Federal Register Representative/DRW, 8701 Morrissette Drive, Springfield, Virginia 22152. SUPPLEMENTARY INFORMATION: The Attorney General has delegated his authority under the Controlled Substances Act to the Administrator of the Drug Enforcement Administration (DEA), 28 CFR 0.100(b). Authority to exercise all necessary functions with respect to the promulgation and implementation of 21 CFR part 1301, incident to the registration of manufacturers, distributors, dispensers, importers, and exporters of controlled substances (other than final orders in connection with suspension, denial, or revocation of registration) has been redelegated to the Assistant Administrator of the DEA Diversion Control Division (‘‘Assistant Administrator’’) pursuant to section 7 of 28 CFR part 0, appendix to subpart R. In accordance with 21 CFR 1301.34(a), this is notice that on July 13, 2017, Cerilliant Corporation, 811 Paloma Drive, Suite A, Round Rock, Texas 78665 applied to be registered as an importer of the following basic classes of controlled substances: mstockstill on DSK30JT082PROD with NOTICES Controlled substance Drug code 3-Fluoro-N-methylcathinone (3–FMC) ............................................................................................................................. Cathinone ........................................................................................................................................................................ Methcathinone ................................................................................................................................................................. 4-Fluoro-N-methylcathinone (4–FMC) ............................................................................................................................. Pentedrone (a-methylaminovalerophenone) ................................................................................................................... Mephedrone (4-Methyl-N-methylcathinone) .................................................................................................................... 4-Methyl-N-ethylcathinone (4–MEC) ............................................................................................................................... Naphyrone ....................................................................................................................................................................... N-Ethylamphetamine ....................................................................................................................................................... N,N-Dimethylamphetamine .............................................................................................................................................. Fenethylline ..................................................................................................................................................................... Methaqualone .................................................................................................................................................................. JWH–250 (1-Pentyl-3-(2-methoxyphenylacetyl) indole) .................................................................................................. SR–18 (Also known as RCS–8) (1-Cyclohexylethyl-3-(2-methoxyphenylacetyl) indole) ................................................ 5-Flouro-UR-144 and XLR11 [1-(5-Fluoro-pentyl)1H-indol-3-yl](2,2,3,3-tetramethylcyclopropyl)methanone ................. AB–FUBINACA (N-(1-amino-3-methyl-1-oxobutan-2-yl)-1-(4-fluorobenzyl)-1H-indazole-3-carboxamide) ..................... JWH–019 (1-Hexyl-3-(1-naphthoyl)indole) ...................................................................................................................... AB–PINACA (N-(1-amino-3-methyl-1-oxobutan-2-yl)-1-pentyl-1H-indazole-3-carboxamide) ......................................... THJ–2201 [1-(5-fluoropentyl)-1H-indazol-3-yl](naphthalen-1-yl)methanone ................................................................... AB–CHMINACA (N-(1-amino-3-methyl-1-oxobutan-2-yl)-1-(cyclohexylmethyl)-1H-indazole-3-carboxamide ................. ADB–PINACA (N-(1-amino-3,3-dimethyl-1-oxobutan-2-yl)-1-pentyl-1H-indazole-3-carboxamide) ................................. APINACA and AKB48 N-(1-Adamantyl)-1-pentyl-1H-indazole-3-carboxamide .............................................................. JWH–081 (1-Pentyl-3-(1-(4-methoxynaphthoyl) indole) .................................................................................................. SR–19 (Also known as RCS–4) (1-Pentyl-3-[(4-methoxy)-benzoyl] indole .................................................................... JWH–018 (also known as AM678) (1-Pentyl-3-(1-naphthoyl)indole) .............................................................................. JWH–122 (1-Pentyl-3-(4-methyl-1-naphthoyl) indole) ..................................................................................................... UR–144 (1-Pentyl-1H-indol-3-yl)(2,2,3,3-tetramethylcyclopropyl)methanone ................................................................. JWH–073 (1-Butyl-3-(1-naphthoyl)indole) ....................................................................................................................... JWH–200 (1-[2-(4-Morpholinyl)ethyl]-3-(1-naphthoyl)indole) .......................................................................................... AM2201 (1-(5-Fluoropentyl)-3-(1-naphthoyl) indole) ....................................................................................................... JWH–203 (1-Pentyl-3-(2-chlorophenylacetyl) indole) ...................................................................................................... PB–22 (Quinolin-8-yl 1-pentyl-1H-indole-3-carboxylate) ................................................................................................. 5F–PB–22 (Quinolin-8-yl 1-(5-fluoropentyl)-1H-indole-3-carboxylate) ............................................................................ Alpha-ethyltryptamine ...................................................................................................................................................... Ibogaine ........................................................................................................................................................................... CP–47,497 (5-(1,1-Dimethylheptyl)-2-[(1R,3S)-3-hydroxycyclohexyl-phenol) ................................................................ CP–47,497 C8 Homologue (5-(1,1-Dimethyloctyl)-2-[(1R,3S)3-hydroxycyclohexyl-phenol) .......................................... Lysergic acid diethylamide .............................................................................................................................................. 2,5-Dimethoxy-4-(n)-propylthiophenethylamine (2C–T–7) .............................................................................................. Marihuana ........................................................................................................................................................................ Parahexyl ......................................................................................................................................................................... Mescaline ......................................................................................................................................................................... 2-(4-Ethylthio-2,5-dimethoxyphenyl) ethanamine (2C–T–2 ) .......................................................................................... 3,4,5-Trimethoxyamphetamine ........................................................................................................................................ 4-Bromo-2,5-dimethoxyamphetamine ............................................................................................................................. 4-Bromo-2,5-dimethoxyphenethylamine .......................................................................................................................... 4-Methyl-2,5-dimethoxyamphetamine ............................................................................................................................. 2,5-Dimethoxyamphetamine ............................................................................................................................................ JWH–398 (1-Pentyl-3-(4-chloro-1-naphthoyl) indole) ...................................................................................................... 3,4-Methylenedioxyamphetamine .................................................................................................................................... 5-Methoxy-3,4-methylenedioxyamphetamine .................................................................................................................. N-Hydroxy-3,4-methylenedioxyamphetamine .................................................................................................................. 3,4-Methylenedioxy-N-ethylamphetamine ....................................................................................................................... 3,4-Methylenedioxymethamphetamine ............................................................................................................................ 4-Methoxyamphetamine .................................................................................................................................................. VerDate Sep<11>2014 17:07 Sep 14, 2017 Jkt 241001 PO 00000 Frm 00081 Fmt 4703 Sfmt 4703 E:\FR\FM\15SEN1.SGM 15SEN1 1233 1235 1237 1238 1246 1248 1249 1258 1475 1480 1503 2565 6250 7008 7011 7012 7019 7023 7024 7031 7035 7048 7081 7104 7118 7122 7144 7173 7200 7201 7203 7222 7225 7249 7260 7297 7298 7315 7348 7360 7374 7381 7385 7390 7391 7392 7395 7396 7398 7400 7401 7402 7404 7405 7411 Schedule I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I 43406 Federal Register / Vol. 82, No. 178 / Friday, September 15, 2017 / Notices mstockstill on DSK30JT082PROD with NOTICES Controlled substance Drug code 5-Methoxy-N-N-dimethyltryptamine ................................................................................................................................. Alpha-methyltryptamine ................................................................................................................................................... Bufotenine ........................................................................................................................................................................ Diethyltryptamine ............................................................................................................................................................. Dimethyltryptamine .......................................................................................................................................................... Psilocybin ......................................................................................................................................................................... Psilocyn ........................................................................................................................................................................... 5-Methoxy-N,N-diisopropyltryptamine ............................................................................................................................. N-Ethyl-1-phenylcyclohexylamine .................................................................................................................................... 1-(1-Phenylcyclohexyl)pyrrolidine .................................................................................................................................... 1-[1-(2-Thienyl)cyclohexyl]piperidine ............................................................................................................................... N-Benzylpiperazine .......................................................................................................................................................... 4-Methyl-alphapyrrolidinopropiophenone (4-MePPP) ..................................................................................................... 2-(2,5-Dimethoxy-4-methylphenyl) ethanamine (2C–D) .................................................................................................. 2-(2,5-Dimethoxy-4-ethylphenyl) ethanamine (2C–E ) .................................................................................................... 2-(2,5-Dimethoxyphenyl) ethanamine (2C–H) ................................................................................................................. 2-(4-Iodo-2,5-dimethoxyphenyl) ethanamine (2C–I) ....................................................................................................... 2-(4-Chloro-2,5-dimethoxyphenyl) ethanamine (2C–C) .................................................................................................. 2-(2,5-Dimethoxy-4-nitro-phenyl) ethanamine (2C–N) .................................................................................................... 2-(2,5-Dimethoxy-4-(n)-propylphenyl) ethanamine (2C–P) ............................................................................................. 2-(4-Isopropylthio)-2,5-dimethoxyphenyl) ethanamine (2C–T–4 ) .................................................................................. MDPV (3,4-Methylenedioxypyrovalerone) ....................................................................................................................... 2-(4-bromo-2,5-dimethoxyphenyl)-N-(2-methoxybenzyl) ethanamine (25B–NBOMe) .................................................... 2-(4-chloro-2,5-dimethoxyphenyl)-N-(2-methoxybenzyl) ethanamine (25C–NBOMe) .................................................... 2-(4-iodo-2,5-dimethoxyphenyl)-N-(2-methoxybenzyl) ethanamine (25I–NBOMe) ......................................................... Methylone (3,4-Methylenedioxy-N-methylcathinone) ...................................................................................................... Butylone ........................................................................................................................................................................... Pentylone ......................................................................................................................................................................... alpha-pyrrolidinopentiophenone (a-PVP) ........................................................................................................................ alpha-pyrrolidinobutiophenone (a-PBP) .......................................................................................................................... AM–694 (1-(5-Fluoropentyl)-3-(2-iodobenzoyl) indole) ................................................................................................... Desomorphine ................................................................................................................................................................. Etorphine (except HCl) .................................................................................................................................................... Codeine methylbromide ................................................................................................................................................... Heroin .............................................................................................................................................................................. Morphine-N-oxide ............................................................................................................................................................ Normorphine .................................................................................................................................................................... Pholcodine ....................................................................................................................................................................... U–47700 (3,4-dichloro-N-[2-dimethylamino)cyclohexy]-N-methylbenzamide) ................................................................ AH–7921 (3,4-dichloro-N-[(1-dimethylamino)cyclohexylmethyl]benzamide)) .................................................................. Acetylmethadol ................................................................................................................................................................ Allylprodine ...................................................................................................................................................................... Alphacetylmethadol except levo-alphacetylmethadol ...................................................................................................... Alphameprodine ............................................................................................................................................................... Alphamethadol ................................................................................................................................................................. Betacetylmethadol ........................................................................................................................................................... Betameprodine ................................................................................................................................................................ Betamethadol ................................................................................................................................................................... Betaprodine ..................................................................................................................................................................... Dextromoramide .............................................................................................................................................................. Dipipanone ....................................................................................................................................................................... Hydroxypethidine ............................................................................................................................................................. Noracymethadol ............................................................................................................................................................... Norlevorphanol ................................................................................................................................................................ Normethadone ................................................................................................................................................................. Racemoramide ................................................................................................................................................................ Trimeperidine ................................................................................................................................................................... 1-Methyl-4-phenyl-4-propionoxypiperidine ...................................................................................................................... Tilidine ............................................................................................................................................................................. Para-Fluorofentanyl ......................................................................................................................................................... 3-Methylfentanyl .............................................................................................................................................................. Alpha-methylfentanyl ....................................................................................................................................................... Acetyl-alpha-methylfentanyl ............................................................................................................................................. Beta-hydroxyfentanyl ....................................................................................................................................................... Beta-hydroxy-3-methylfentanyl ........................................................................................................................................ Alpha-methylthiofentanyl ................................................................................................................................................. 3-Methylthiofentanyl ......................................................................................................................................................... Thiofentanyl ..................................................................................................................................................................... Methamphetamine ........................................................................................................................................................... Methylphenidate .............................................................................................................................................................. Amobarbital ...................................................................................................................................................................... Pentobarbital .................................................................................................................................................................... Secobarbital ..................................................................................................................................................................... Glutethimide ..................................................................................................................................................................... VerDate Sep<11>2014 17:07 Sep 14, 2017 Jkt 241001 PO 00000 Frm 00082 Fmt 4703 Sfmt 4703 E:\FR\FM\15SEN1.SGM 15SEN1 7431 7432 7433 7434 7435 7437 7438 7439 7455 7458 7470 7493 7498 7508 7509 7517 7518 7519 7521 7524 7532 7535 7536 7537 7538 7540 7541 7542 7545 7546 7694 9055 9056 9070 9200 9307 9313 9314 9547 9551 9601 9602 9603 9604 9605 9607 9608 9609 9611 9613 9622 9627 9633 9634 9635 9645 9646 9661 9750 9812 9813 9814 9815 9830 9831 9832 9833 9835 1105 1724 2125 2270 2315 2550 Schedule I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I II II II II II II 43407 Federal Register / Vol. 82, No. 178 / Friday, September 15, 2017 / Notices Controlled substance Drug code Nabilone ........................................................................................................................................................................... 1-Phenylcyclohexylamine ................................................................................................................................................ Phencyclidine ................................................................................................................................................................... Phenylacetone ................................................................................................................................................................. 1-Piperidinocyclohexanecarbonitrile ................................................................................................................................ Alphaprodine .................................................................................................................................................................... Dihydrocodeine ................................................................................................................................................................ Ecgonine .......................................................................................................................................................................... Ethylmorphine .................................................................................................................................................................. Levomethorphan .............................................................................................................................................................. Levorphanol ..................................................................................................................................................................... Meperidine ....................................................................................................................................................................... Dextropropoxyphene, bulk (non-dosage forms) .............................................................................................................. Levo-alphacetylmethadol ................................................................................................................................................. Noroxymorphone ............................................................................................................................................................. Racemethorphan ............................................................................................................................................................. Alfentanil .......................................................................................................................................................................... Remifentanil ..................................................................................................................................................................... Sufentanil ......................................................................................................................................................................... Carfentanil ....................................................................................................................................................................... Tapentadol ....................................................................................................................................................................... The company plans to import small quantities of the listed controlled substances for the manufacture of analytical reference standards and distribution to their research and forensic customers. In reference to drug code 7360 the company plans to import a synthetic cannabidiol. No other activity for this drug code is authorized for this registration. Placement of these drug codes onto the company’s registration does not translate into automatic approval of subsequent permit applications to import controlled substances. Approval of permit applications will occur only when the registrant’s business activity is consistent with what is authorized under 21 U.S.C. 952(a)(2). Authorization will not extend to the import of FDA approval or non-approved finished dosage forms for commercial sale. Dated: August 31, 2017. Demetra Ashley, Acting Assistant Administrator. [FR Doc. 2017–19067 Filed 9–14–17; 8:45 am] BILLING CODE 4410–09–P DEPARTMENT OF JUSTICE National Institute of Justice mstockstill on DSK30JT082PROD with NOTICES [OMB Number 1121–NEW] Agency Information Collection Activities: Proposed New Information Collection Activity; Comment Request, Proposed Study Entitled ‘‘Evaluation of the Bureau of Justice Assistance Sexual Assault Kit Initiative’’ National Institute of Justice, U.S. Department of Justice. AGENCY: VerDate Sep<11>2014 17:07 Sep 14, 2017 Jkt 241001 ACTION: 30-Day notice. The Department of Justice (DOJ), Office of Justice Programs, National Institute of Justice, will be submitting the following information collection request to the Office of Management and Budget (OMB) for review and approval in accordance with the Paperwork Reduction Act of 1995. DATES: Comments are encouraged and will be accepted for 60 days until November 14, 2017. FOR FURTHER INFORMATION CONTACT: Written comments and/or suggestions regarding the items contained in this notice, especially the estimated public burden and associated response time, should be directed to Christine Crossland, National Institute of Justice, Office of Research & Evaluation, 810 Seventh Street NW., Washington, DC 20531 (overnight 20001) or via email at christine.crossland@ojp.usdoj.gov. Written comments and/or suggestions can also be sent to the Office of Management and Budget, Office of Information and Regulatory Affairs, Attention Department of Justice Desk Officer, Washington, DC 20503 or sent to OIRA_submissions@omb.eop.gov. SUPPLEMENTARY INFORMATION: This process is conducted in accordance with 5 CFR 1320.10. Written comments and suggestions from the public and affected agencies concerning the proposed collection of information are encouraged. Your comments should address one or more of the following four points: —Evaluate whether the proposed collection of information is necessary for the proper performance of the functions of the National Institute of SUMMARY: PO 00000 Frm 00083 Fmt 4703 Sfmt 4703 7379 7460 7471 8501 8603 9010 9120 9180 9190 9210 9220 9230 9273 9648 9668 9732 9737 9739 9740 9743 9780 Schedule II II II II II II II II II II II II II II II II II II II II II Justice, including whether the information will have practical utility; —Evaluate the accuracy of the agency’s estimate of the burden of the proposed collection of information, including the validity of the methodology and assumptions used; —Evaluate whether, and if so how, the quality, utility, and clarity of the information to be collected can be enhanced; and —Minimize the burden of the collection of information on those who are to respond, including through the use of appropriate automated, electronic, mechanical, or other technological collection techniques or other forms of information technology, e.g., permitting electronic submission of responses. Overview of This Information Collection 1. Type of Information Collection: Site visits, which will include individual and group interviews. 2. The Title of the Form/Collection: Evaluation of the Bureau of Justice Assistance Sexual Assault Kit Initiative. 3. The agency form number, if any, and the applicable component of the Department sponsoring the collection: The applicable component within the U.S. Department of Justice is the National Institute of Justice in the Office of Justice Programs. 4. Affected public who will be asked or required to respond, as well as a brief abstract: Sexual assault kits (SAKs) are invaluable tools used in investigations to collect evidence such as DNA and to document injuries from alleged victims; this evidence in turn is used to identify and prosecute offenders and to exonerate innocent suspects. Despite the importance of SAKs, backlogs of E:\FR\FM\15SEN1.SGM 15SEN1

Agencies

[Federal Register Volume 82, Number 178 (Friday, September 15, 2017)]
[Notices]
[Pages 43404-43407]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2017-19067]


=======================================================================
-----------------------------------------------------------------------

DEPARTMENT OF JUSTICE

Drug Enforcement Administration

[Docket No. DEA-392]


Importer of Controlled Substances Application: Cerilliant 
Corporation

ACTION: Notice of application.

-----------------------------------------------------------------------

DATES: Registered bulk manufacturers of the affected basic classes, and 
applicants therefore, may file written comments on or objections to the 
issuance of the proposed registration on or before October 16, 2017. 
Such persons may also file a written request

[[Page 43405]]

for a hearing on the application on or before October 16, 2017.

ADDRESSES: Written comments should be sent to: Drug Enforcement 
Administration, Attention: DEA Federal Register Representative/DRW, 
8701 Morrissette Drive, Springfield, Virginia 22152. All requests for 
hearing must be sent to: Drug Enforcement Administration, Attn: 
Administrator, 8701 Morrissette Drive, Springfield, Virginia 22152. All 
requests for hearing should also be sent to: (1) Drug Enforcement 
Administration, Attn: Hearing Clerk/LJ, 8701 Morrissette Drive, 
Springfield, Virginia 22152; and (2) Drug Enforcement Administration, 
Attn: DEA Federal Register Representative/DRW, 8701 Morrissette Drive, 
Springfield, Virginia 22152.

SUPPLEMENTARY INFORMATION: The Attorney General has delegated his 
authority under the Controlled Substances Act to the Administrator of 
the Drug Enforcement Administration (DEA), 28 CFR 0.100(b). Authority 
to exercise all necessary functions with respect to the promulgation 
and implementation of 21 CFR part 1301, incident to the registration of 
manufacturers, distributors, dispensers, importers, and exporters of 
controlled substances (other than final orders in connection with 
suspension, denial, or revocation of registration) has been redelegated 
to the Assistant Administrator of the DEA Diversion Control Division 
(``Assistant Administrator'') pursuant to section 7 of 28 CFR part 0, 
appendix to subpart R.
    In accordance with 21 CFR 1301.34(a), this is notice that on July 
13, 2017, Cerilliant Corporation, 811 Paloma Drive, Suite A, Round 
Rock, Texas 78665 applied to be registered as an importer of the 
following basic classes of controlled substances:

------------------------------------------------------------------------
        Controlled substance            Drug code          Schedule
------------------------------------------------------------------------
3-Fluoro-N-methylcathinone (3-FMC).            1233  I
Cathinone..........................            1235  I
Methcathinone......................            1237  I
4-Fluoro-N-methylcathinone (4-FMC).            1238  I
Pentedrone ([alpha]-                           1246  I
 methylaminovalerophenone).
Mephedrone (4-Methyl-N-                        1248  I
 methylcathinone).
4-Methyl-N-ethylcathinone (4-MEC)..            1249  I
Naphyrone..........................            1258  I
N-Ethylamphetamine.................            1475  I
N,N-Dimethylamphetamine............            1480  I
Fenethylline.......................            1503  I
Methaqualone.......................            2565  I
JWH-250 (1-Pentyl-3-(2-                        6250  I
 methoxyphenylacetyl) indole).
SR-18 (Also known as RCS-8) (1-                7008  I
 Cyclohexylethyl-3-(2-
 methoxyphenylacetyl) indole).
5-Flouro-UR-144 and XLR11 [1-(5-               7011  I
 Fluoro-pentyl)1H-indol-3-
 yl](2,2,3,3-
 tetramethylcyclopropyl)methanone.
AB-FUBINACA (N-(1-amino-3-methyl-1-            7012  I
 oxobutan-2-yl)-1-(4-fluorobenzyl)-
 1H-indazole-3-carboxamide).
JWH-019 (1-Hexyl-3-(1-                         7019  I
 naphthoyl)indole).
AB-PINACA (N-(1-amino-3-methyl-1-              7023  I
 oxobutan-2-yl)-1-pentyl-1H-
 indazole-3-carboxamide).
THJ-2201 [1-(5-fluoropentyl)-1H-               7024  I
 indazol-3-yl](naphthalen-1-
 yl)methanone.
AB-CHMINACA (N-(1-amino-3-methyl-1-            7031  I
 oxobutan-2-yl)-1-
 (cyclohexylmethyl)-1H-indazole-3-
 carboxamide.
ADB-PINACA (N-(1-amino-3,3-dimethyl-           7035  I
 1-oxobutan-2-yl)-1-pentyl-1H-
 indazole-3-carboxamide).
APINACA and AKB48 N-(1-Adamantyl)-1-           7048  I
 pentyl-1H-indazole-3-carboxamide.
JWH-081 (1-Pentyl-3-(1-(4-                     7081  I
 methoxynaphthoyl) indole).
SR-19 (Also known as RCS-4) (1-                7104  I
 Pentyl-3-[(4-methoxy)-benzoyl]
 indole.
JWH-018 (also known as AM678) (1-              7118  I
 Pentyl-3-(1-naphthoyl)indole).
JWH-122 (1-Pentyl-3-(4-methyl-1-               7122  I
 naphthoyl) indole).
UR-144 (1-Pentyl-1H-indol-3-                   7144  I
 yl)(2,2,3,3-
 tetramethylcyclopropyl)methanone.
JWH-073 (1-Butyl-3-(1-                         7173  I
 naphthoyl)indole).
JWH-200 (1-[2-(4-Morpholinyl)ethyl]-           7200  I
 3-(1-naphthoyl)indole).
AM2201 (1-(5-Fluoropentyl)-3-(1-               7201  I
 naphthoyl) indole).
JWH-203 (1-Pentyl-3-(2-                        7203  I
 chlorophenylacetyl) indole).
PB-22 (Quinolin-8-yl 1-pentyl-1H-              7222  I
 indole-3-carboxylate).
5F-PB-22 (Quinolin-8-yl 1-(5-                  7225  I
 fluoropentyl)-1H-indole-3-
 carboxylate).
Alpha-ethyltryptamine..............            7249  I
Ibogaine...........................            7260  I
CP-47,497 (5-(1,1-Dimethylheptyl)-2-           7297  I
 [(1R,3S)-3-hydroxycyclohexyl-
 phenol).
CP-47,497 C8 Homologue (5-(1,1-                7298  I
 Dimethyloctyl)-2-[(1R,3S)3-
 hydroxycyclohexyl-phenol).
Lysergic acid diethylamide.........            7315  I
2,5-Dimethoxy-4-(n)-                           7348  I
 propylthiophenethylamine (2C-T-7).
Marihuana..........................            7360  I
Parahexyl..........................            7374  I
Mescaline..........................            7381  I
2-(4-Ethylthio-2,5-dimethoxyphenyl)            7385  I
 ethanamine (2C-T-2 ).
3,4,5-Trimethoxyamphetamine........            7390  I
4-Bromo-2,5-dimethoxyamphetamine...            7391  I
4-Bromo-2,5-dimethoxyphenethylamine            7392  I
4-Methyl-2,5-dimethoxyamphetamine..            7395  I
2,5-Dimethoxyamphetamine...........            7396  I
JWH-398 (1-Pentyl-3-(4-chloro-1-               7398  I
 naphthoyl) indole).
3,4-Methylenedioxyamphetamine......            7400  I
5-Methoxy-3,4-                                 7401  I
 methylenedioxyamphetamine.
N-Hydroxy-3,4-                                 7402  I
 methylenedioxyamphetamine.
3,4-Methylenedioxy-N-                          7404  I
 ethylamphetamine.
3,4-Methylenedioxymethamphetamine..            7405  I
4-Methoxyamphetamine...............            7411  I

[[Page 43406]]

 
5-Methoxy-N-N-dimethyltryptamine...            7431  I
Alpha-methyltryptamine.............            7432  I
Bufotenine.........................            7433  I
Diethyltryptamine..................            7434  I
Dimethyltryptamine.................            7435  I
Psilocybin.........................            7437  I
Psilocyn...........................            7438  I
5-Methoxy-N,N-diisopropyltryptamine            7439  I
N-Ethyl-1-phenylcyclohexylamine....            7455  I
1-(1-Phenylcyclohexyl)pyrrolidine..            7458  I
1-[1-(2-                                       7470  I
 Thienyl)cyclohexyl]piperidine.
N-Benzylpiperazine.................            7493  I
4-Methyl-                                      7498  I
 alphapyrrolidinopropiophenone (4-
 MePPP).
2-(2,5-Dimethoxy-4-methylphenyl)               7508  I
 ethanamine (2C-D).
2-(2,5-Dimethoxy-4-ethylphenyl)                7509  I
 ethanamine (2C-E ).
2-(2,5-Dimethoxyphenyl) ethanamine             7517  I
 (2C-H).
2-(4-Iodo-2,5-dimethoxyphenyl)                 7518  I
 ethanamine (2C-I).
2-(4-Chloro-2,5-dimethoxyphenyl)               7519  I
 ethanamine (2C-C).
2-(2,5-Dimethoxy-4-nitro-phenyl)               7521  I
 ethanamine (2C-N).
2-(2,5-Dimethoxy-4-(n)-                        7524  I
 propylphenyl) ethanamine (2C-P).
2-(4-Isopropylthio)-2,5-                       7532  I
 dimethoxyphenyl) ethanamine (2C-T-
 4 ).
MDPV (3,4-                                     7535  I
 Methylenedioxypyrovalerone).
2-(4-bromo-2,5-dimethoxyphenyl)-N-             7536  I
 (2-methoxybenzyl) ethanamine (25B-
 NBOMe).
2-(4-chloro-2,5-dimethoxyphenyl)-N-            7537  I
 (2-methoxybenzyl) ethanamine (25C-
 NBOMe).
2-(4-iodo-2,5-dimethoxyphenyl)-N-(2-           7538  I
 methoxybenzyl) ethanamine (25I-
 NBOMe).
Methylone (3,4-Methylenedioxy-N-               7540  I
 methylcathinone).
Butylone...........................            7541  I
Pentylone..........................            7542  I
alpha-pyrrolidinopentiophenone                 7545  I
 ([alpha]-PVP).
alpha-pyrrolidinobutiophenone                  7546  I
 ([alpha]-PBP).
AM-694 (1-(5-Fluoropentyl)-3-(2-               7694  I
 iodobenzoyl) indole).
Desomorphine.......................            9055  I
Etorphine (except HCl).............            9056  I
Codeine methylbromide..............            9070  I
Heroin.............................            9200  I
Morphine-N-oxide...................            9307  I
Normorphine........................            9313  I
Pholcodine.........................            9314  I
U-47700 (3,4-dichloro-N-[2-                    9547  I
 dimethylamino)cyclohexy]-N-
 methylbenzamide).
AH-7921 (3,4-dichloro-N-[(1-                   9551  I
 dimethylamino)cyclohexylmethyl]ben
 zamide)).
Acetylmethadol.....................            9601  I
Allylprodine.......................            9602  I
Alphacetylmethadol except levo-                9603  I
 alphacetylmethadol.
Alphameprodine.....................            9604  I
Alphamethadol......................            9605  I
Betacetylmethadol..................            9607  I
Betameprodine......................            9608  I
Betamethadol.......................            9609  I
Betaprodine........................            9611  I
Dextromoramide.....................            9613  I
Dipipanone.........................            9622  I
Hydroxypethidine...................            9627  I
Noracymethadol.....................            9633  I
Norlevorphanol.....................            9634  I
Normethadone.......................            9635  I
Racemoramide.......................            9645  I
Trimeperidine......................            9646  I
1-Methyl-4-phenyl-4-                           9661  I
 propionoxypiperidine.
Tilidine...........................            9750  I
Para-Fluorofentanyl................            9812  I
3-Methylfentanyl...................            9813  I
Alpha-methylfentanyl...............            9814  I
Acetyl-alpha-methylfentanyl........            9815  I
Beta-hydroxyfentanyl...............            9830  I
Beta-hydroxy-3-methylfentanyl......            9831  I
Alpha-methylthiofentanyl...........            9832  I
3-Methylthiofentanyl...............            9833  I
Thiofentanyl.......................            9835  I
Methamphetamine....................            1105  II
Methylphenidate....................            1724  II
Amobarbital........................            2125  II
Pentobarbital......................            2270  II
Secobarbital.......................            2315  II
Glutethimide.......................            2550  II

[[Page 43407]]

 
Nabilone...........................            7379  II
1-Phenylcyclohexylamine............            7460  II
Phencyclidine......................            7471  II
Phenylacetone......................            8501  II
1-Piperidinocyclohexanecarbonitrile            8603  II
Alphaprodine.......................            9010  II
Dihydrocodeine.....................            9120  II
Ecgonine...........................            9180  II
Ethylmorphine......................            9190  II
Levomethorphan.....................            9210  II
Levorphanol........................            9220  II
Meperidine.........................            9230  II
Dextropropoxyphene, bulk (non-                 9273  II
 dosage forms).
Levo-alphacetylmethadol............            9648  II
Noroxymorphone.....................            9668  II
Racemethorphan.....................            9732  II
Alfentanil.........................            9737  II
Remifentanil.......................            9739  II
Sufentanil.........................            9740  II
Carfentanil........................            9743  II
Tapentadol.........................            9780  II
------------------------------------------------------------------------

    The company plans to import small quantities of the listed 
controlled substances for the manufacture of analytical reference 
standards and distribution to their research and forensic customers.
    In reference to drug code 7360 the company plans to import a 
synthetic cannabidiol. No other activity for this drug code is 
authorized for this registration.
    Placement of these drug codes onto the company's registration does 
not translate into automatic approval of subsequent permit applications 
to import controlled substances. Approval of permit applications will 
occur only when the registrant's business activity is consistent with 
what is authorized under 21 U.S.C. 952(a)(2). Authorization will not 
extend to the import of FDA approval or non-approved finished dosage 
forms for commercial sale.

    Dated: August 31, 2017.
Demetra Ashley,
Acting Assistant Administrator.
[FR Doc. 2017-19067 Filed 9-14-17; 8:45 am]
 BILLING CODE 4410-09-P